Source-grounded facts extracted from CUMBERLAND PHARMACEUTICALS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CUMBERLAND PHARMACEUTICALS INC reported three months ended March 31, 2026 results: revenue $9.1 million, net income net loss for the first quarter of 2026 was approximately $3.3 million, EPS $0.13 per share.
“Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We”
Material Agreements
CUMBERLAND PHARMACEUTICALS INC entered into Asset Purchase Agreement with Apotex Inc. valued at $100,000,000 (effective 2026-04-22).
“On April 22, 2026, Cumberland Pharmaceuticals Inc. (the “ Company ” or “ Cumberland ”) entered into a strategic transaction (the “ Transaction ”) to integrate its commercial products with the U.S. branded business of an affiliate of Apotex Inc., a corporation incorporated under the laws of the Province of Ontario (“ Apotex ”), in exchange for $100,000,000 payable at the closing of the Transaction.”
Debt Financings
CUMBERLAND PHARMACEUTICALS INC incurred revolving credit of up to $15 million with Pinnacle Bank at Benchmark Term SOFR plus 2.75% maturing October 1, 2027.
“The Amendment provides for a principal available for borrowing of up to $15 million.”
Earnings Releases
CUMBERLAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $8.5 million.
“Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders’ equity. “It”
Shareholder Votes
CUMBERLAND PHARMACEUTICALS INC shareholders approved Ratification of appointment of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for year ending December 31, 2024 at the 2024-04-23 meeting.
“Appointment of Carr, Riggs & Ingram LLC as our independent registered public accounting firm for the year ending December 31, 2024 11,189,440 15,502 — 28,560 99.9%”
Shareholder Votes
CUMBERLAND PHARMACEUTICALS INC shareholders approved Election of two Class II Directors at the 2024-04-23 meeting.
“For Against Withheld Abstentions % of Votes in Favor Martin S. Brown, Jr. 8,544,756 — 352,239 — 96.0% James R. Jones 8,411,468 — 485,527 — 94.5%”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.